

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of	: Meade, C. J. M. et al) Art Unit:
U.S. Appln. No.	: 10/614,382) Examiner:

Confirmation No.: 7418 U.S. Filing Date: 07/07/2003

Title of Invention: Pharmaceutical Compositions Based on Anticholinergics and EFGR

Kinase Inhibitors

Attny. Docket No.: 1/1365

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

October 8, 2003

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A and B) with copies of all references cited therein. This is being submitted pursuant to 37 C.F.R. §1.56 and before the mailing of a first Office Action on the merits, pursuant to 37 CFR § 1.97(b).

It should be noted that the references listed in the Information Disclosure Statement have been cited in the International Search Report (ISR) for PCT/EP 03/06788, which corresponds to the present US application. A copy of that ISR is enclosed herewith.

\boxtimes	1.97(b)	This Statement is being filed: i) within three (3) months of the filing
date o	f a natio	al application other than a continued prosecution application under 33 C.F.R.
§1.53	(d); ii) v	thin three (3) months of the date of entry of the national stage as set forth in
37 C.I	F.R. §1.4	1 in an international application; iii) before the mailing of a first Office action
on the	merits;	r iv) before the mailing of a first Office action after the filing of a request for
contin	ued exai	ination under 37 C.F.R. §1.114.
_		
	. ,	This Statement is being filed after the time period specified in 37
	•	, but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a
		ince under 37 C.F.R. §1.311, or iii) an action that otherwise closes
prosec	ution in	he application. This Statement is being accompanied by:
		A
		A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e)).
	counte	Each item of information contained in the instant information disclosure ent was first cited in any communication from a foreign patent office in a rpart foreign application not more than three (3) months prior to the filing of tant information disclosure statement; or
	foreign making inform C.F.R.	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 §1.56(c) more than three (3) months prior to the filing of the instant ation disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte n sect	rpart ap	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated (c) more than thirty (30) days prior to the filing of the accompanying sclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Philip I. Datlow

Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4542 Date: October 8, 2003 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on October 8, 2003.

Philip I. Datlow, Reg. No. 41,482

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE
INFORMATION DISCLOSURE
Filing Date

07/07/2003
First Named Inventor
Art Unit

(Use as many sheets as necessary)

Sheet

Examiner Name

Attorney Docket Number | 1/1365

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 2,927,925 A	03/08/1960	Zaugg, H. E.	
		^{∪S-} 6,455,524 B1	09/24/2002	Bozung, K-H. et al	
		US-			
		US-			
		us-			
······································		US-			
		US-			manufactural visual
		US-			
***************************************		US-			
	·	US-			
		US-			
		US-			

2

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials* No.	No.'	Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°
		WO 00/69468 A	11/23/2000	BI Pharma		
		WO 02/32899 A	04/25/2002	BI Pharma		

	<u> </u>			•••••••••••••••••••••••••••••••••••••••	***************************************	

Examiner	Date	
Signature	Considere	
-	i i	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/614,382 INFORMATION DISCLOSURE Filing Date 07/07/2003 STATEMENT BY APPLICANT First Named Inventor Christopher J. M. MEADE Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number 1/1365 Sheet 2 2

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		MEISSNER, H. ET AL; "Anticholinergics Which May Be Used As Medicamdents As Well As Processes For Preparing Them"; US Publication No. 2002115680 A1; 08/22/2002; Attorney Docket No. 1/1151			
Evaminer		Data	$\overline{\ \ }$		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Signature

Considered

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.